“ECMO Anticoagulation: Should We Consider Bivalirudin Over Heparin?”

Introduction: Extracorporeal membrane oxygenation (ECMO) requires systemic anticoagulation to prevent thrombotic events within the circuit. The use of unfractionated heparin has been the traditional anticoagulant of choice. Bivalirudin, a direct thrombin inhibitor, offers an alternative that has theoretical and observed benefits. The purpose of this clinical review is to evaluate whether bivalirudin provides superior safety and efficacy compared to UFH in ECMO patients. Methods: PubMed was searched with a specific search strategy using key terms “Extracorporeal membrane oxygenation” AND “indirect anticoagulants” AND “deep vein thrombosis”. Operators and filters narrowed the results to four relevant, quality articles for review. Results: In four studies, bivalirudin showed a statistically significant reduction in major bleeding events and ECMO circuit thrombosis compared to UFH. Three studies showed evidence of decrease in-hospital mortality. In one study, heparin and bivalirudin had comparable overall in-hospital mortality rates. Patients treated with bivalirudin had an improved time-in-therapeutic range for APTT, lower transfusion rates, and reduced incidence of HIT. Discussion: The articles reviewed suggest that bivalirudin may offer clinical advantages over UFH in ECMO anticoagulation. Bivalirudin studies suggest more predictable pharmacokinetics, lower rates of bleeding, and fewer cases of circuit thrombosis. Existing evidence is limited by the use of retrospective studies and inconsistencies in the management of ECMO. Further research is needed to determine whether bivalirudin should replace UFH as standard anticoagulation in ECMO.